Bristol-Myers Squibb Company (BMY)

53.97
0.42 0.77
NYSE : Health Care
Prev Close 54.39
Open 54.29
Day Low/High 53.90 / 54.82
52 Wk Low/High 46.01 / 77.12
Volume 4.97M
Avg Volume 9.05M
Exchange NYSE
Shares Outstanding 1.65B
Market Cap 89.60B
EPS 2.70
P/E Ratio 18.89
Div & Yield 1.56 (2.90%)

Latest News

European Medicines Agency Validates Application For Bristol-Myers Squibb's Sprycel (dasatinib) In Children With Chronic Myelogenous Leukemia

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib) to treat children and...

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program And Commitment To Exploring Novel Combinations At ASCO 2017

Bristol-Myers Squibb Company (NYSE:BMY) today announced that more than 80 presentations, including 16 oral presentations and seven poster discussions, highlighting data from Company-sponsored studies, collaborations...

Cramer: Carl Icahn Was Right to Sell Apple at $95

Cramer: Carl Icahn Was Right to Sell Apple at $95

What's right for a hedge fund manager sitting on a big gain, isn't necessarily right for you.

Bristol-Myers Squibb To Take Part In UBS Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York.

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?

Allergan Starts 'Pivotal' 2017 With a Beat, Plus Jim Cramer's Take

Allergan Starts 'Pivotal' 2017 With a Beat, Plus Jim Cramer's Take

Allergan shares had risen $2.55, or 1.05%, in premarket trading to $244.50.

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

A roundup of Cramer's comments on stocks of interest to viewers.

M&A Talks May Take Center Stage in Allergan's 1Q Earnings Call

M&A Talks May Take Center Stage in Allergan's 1Q Earnings Call

Pfizer CEO Ian Read last week was forced to field questions about M&A and there's a good chance Allergan won't be any different.

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.

Back to Earnings Next Week: Cramer's 'Mad Money' Recap (Friday 5/5/17)

Back to Earnings Next Week: Cramer's 'Mad Money' Recap (Friday 5/5/17)

With the Fed and the healthcare vote out of the way, markets will focus on earnings in the week ahead.

Bristol-Myers Stock Falls Following Ratings Cut at BMO

Bristol-Myers Stock Falls Following Ratings Cut at BMO

BMO cut the company to 'Underperform.'

Analysts' Actions -- Anadarko, FireEye, Bristol-Myers, Twilio and More

Analysts' Actions -- Anadarko, FireEye, Bristol-Myers, Twilio and More

Here are Wednesday's top research calls, including downgrades for Anadarko Petroleum, Twilio and Bristol-Myers Squibb, and an upgrade for FireEye.

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For Squamous Cell Cancer Of The Head And Neck In Adults Progressing On Or After Platinum-based Therapy

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in...

China FDA Approves Country's First All-Oral Regimen For Chronic Hepatitis C, Daklinza® (daclatasvir) In Combination With Sunvepra® (asunaprevir)

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the China Food and Drug Administration (CFDA) has approved a direct-acting antiviral regimen comprised of Daklinza ® (daclatasvir) and Sunvepra ®...

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.

Strong Sales for Opdivo and Eliquis Drive Bristol-Myers' Solid Q1

Strong Sales for Opdivo and Eliquis Drive Bristol-Myers' Solid Q1

Sales of cancer drug Opdivo were up 60% year-over-year, while sales of blood thinner Eliquis grew 50%.

PayPal Propels Nasdaq to New Record; Dow and S&P 500 Post Small Gains

PayPal Propels Nasdaq to New Record; Dow and S&P 500 Post Small Gains

Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.